Dermata Therapeutics (NASDAQ:DRMAW – Get Free Report) is expected to release its resultson Wednesday, May 20th. Analysts expect Dermata Therapeutics to post earnings of ($0.53) per share for the quarter.
Dermata Therapeutics Price Performance
Shares of DRMAW stock opened at $0.01 on Wednesday. The firm has a 50-day moving average price of $0.02 and a 200 day moving average price of $0.02. Dermata Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.03.
Dermata Therapeutics Company Profile
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.
The company’s lead pipeline includes a selective topical PI3K? inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.
Featured Articles
- Five stocks we like better than Dermata Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
